In the article titled “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease” [1], reference [] was incorrectly added as follows:“Y. Chen, S.-C. Xu, and R.-D. Duan, ‘Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells,’ Lipids in Health and Disease, vol. 14, no. 1, article 130, 2015.”It should be replaced with the following reference:“Chen Y, et al. Enhanced colonic tumorigenesis in alkaline sphingomyelinase (NPP7) knockout mice. Mol Cancer Ther, 14:1, 259-67, 2015.”
Corrigendum | Open Access
Corrigendum to “Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease”
Received05 Oct 2016
Accepted20 Oct 2016
Published14 Nov 2016
References
P.-F. Bryan, C. Karla, M.-T. Edgar Alejandro, E.-P. Sara Elva, F. Gemma, and C. Luz, “Sphingolipids as mediators in the crosstalk between microbiota and intestinal cells: implications for inflammatory bowel disease,” Mediators of Inflammation, vol. 2016, Article ID 9890141, 11 pages, 2016.
View at: Publisher Site | Google Scholar
Copyright
Copyright © 2016 Bryan Phillips-Farfán et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.